Connect to other sites within the UBM Medica Network
Alisertib Shows Promise in Soft-Tissue Sarcoma
Alisertib yielded promising progression-free survival in advanced/metastatic soft-tissue sarcoma patients, though it did not meet its primary response rate endpoint.
Genomic Analysis Finds Large Burden of Genetic Risk in Sarcoma Patients
A comprehensive genomic analysis of more than a thousand sarcoma patients found that about half had putatively pathogenic variations in either known or novel cancer genes.
Patient With Abdominal Inflammatory Myofibroblastic Tumor
A 37-year-old Lebanese male with no significant past medical history initially presented with an increase in abdominal girth over a few weeks with worsening shortness of breath, nausea, and intermittent vomiting.
Fusion-Negative Sarcoma Survivors Have Increased Risk of Second Malignancies
Survivors of fusion-negative sarcomas have a higher risk of developing a second malignant neoplasm than those who had fusion-positive sarcomas.
Selinexor Shows Promise in Phase I Sarcoma Trial
A phase I trial of selinexor found the drug was reasonably well tolerated and showed some activity in patients with advanced soft-tissue or bone sarcoma with progressive disease.
Zoledronate Fails to Improve Outcomes With Chemo in Osteosarcoma
Zoledronate in combination with chemotherapy failed to improve outcomes over chemotherapy alone in patients with osteosarcoma.
Three SNPs Associated With Overall Survival in Pediatric Ewing Sarcoma
Three single-nucleotide polymorphisms were identified that are significantly associated with OS in two separate cohorts of pediatric Ewing sarcoma patients.
Drug Shows 10-Month Survival Improvement in Sarcoma
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.
Slide Show: Gastrointestinal Stromal Tumors
This slide show features a CT image, and pathology images of gastrointestinal stromal tumors (GISTs) arising in the stomach using H&E, CD34, and c-Kit staining.
By clicking Accept, you agree to become a member of the UBM Medica Community.